RUTHERFORD, N.J. and HYDERABAD, India, May 22, 2015 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"), an emerging leader in DNA-based cancer diagnostics, announced today the appointment of Mandar Kulkarni, PhD. as Chief Technology Officer (CTO) of Cancer Genetics, India, based in Hyderabad. In his role, Kulkarni will lead efforts to expand CG India's technology programs and initiatives with a focus on accelerating development and innovation. Dr. Kulkarni will report directly to Cancer Genetics CEO, Panna Sharma.
Kulkarni joins CGI with over five years of experience in both clinical and genomic development and will be focused initially on three key strategic areas. Dr. Kulkarni's initiatives include enhancing and accelerating the Company's efforts in offering next-generation sequencing (NGS) based tests to leading research institutions, clinical partners and biopharma companies and strengthening CG India's partnerships with cancer centers, and hospitals. Dr. Kulkarni will also spearhead the development of an oncology-focused knowledge base that will include genomic information geared toward facilitating the personalization of treatment for Indian populations. The database will also be used to inform and accelerate discovery and clinical development.
"Mandar's expertise in leading teams focused on next-generation sequencing and bioinformatics is completely aligned with CG India's vision," said Panna Sharma, President and CEO of Cancer Genetics. "His in-depth cancer research background, both as a manager and as a scientist; his ability to counsel clinical and biopharma clients to ensure their objectives are not only met, but exceeded; and his extensive knowledge of the needs of the Indian market make him a great fit for CGI."
Prior to joining CG India, Kulkarni was Head of molecular biology and genomics at Sandor Lifesciences, where his team designed and executed next-generation sequencing, bioinformatics, and microarray initiatives. Kulkarni was also a senior scientist at M/Z Diagnostics where he developed and clinically validated a diagnostic assay for rapid detection of multi-drug resistant bacterial infections.
"I am joining at a pivotal time in CGI's global growth. We have a strong team in India and together we look forward to delivering innovative, transformative solutions and genomic services throughout India," said Kulkarni. "India has a growing need for advanced oncology services and CG India's sophisticated and innovative offering will help improve cancer treatment and affect many lives in our community in a positive way."
Dr. Kulkarni received his Bachelor of Science degree from Pune University and the University of Wisconsin and earned a doctorate degree from Purdue University. He completed his postdoctoral training at Yale School of Medicine.
About Cancer Genetics
Cancer Genetics Inc. is an emerging leader in DNA-based cancer diagnostics. Our tests target difficult to diagnose hematological, urogenital and HPV-associated cancers. They are designed to guide the prognosis and treatment of these cancers with the goal of improving outcomes for patients. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.
We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals and biopharmaceutical companies. Our state-of-the-art reference labs are CLIA certified and CAP accredited in the US and have licensure from several states including New York State.
CONTACT: For more information, please visit or follow us: Internet: http://www.cancergenetics.com
Source:Cancer Genetics, Inc.